6,7-dimethoxy-2-phenylquinoxaline

specific for platelet-derived growth factor

Also Known As:

AG 1295; AG-1295; AG1295

Networked: 11 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Benzylidene Compounds: 10
        Tyrphostins: 183
        6,7-dimethoxy-2-phenylquinoxaline: 11
- Nitriles: 227
  - Tyrphostins: 183
    - 6,7-dimethoxy-2-phenylquinoxaline: 11
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinoxalines: 324
      - Tyrphostins: 183
        6,7-dimethoxy-2-phenylquinoxaline: 11

Experts

1.	Hu, Zhongdong: 1 article (08/2017)
2.	Ji, Shuang: 1 article (08/2017)
3.	Jiang, Keguo: 1 article (08/2017)
4.	Jin, Fuquan: 1 article (08/2017)
5.	Liu, Yujie: 1 article (08/2017)
6.	Ma, Junfang: 1 article (08/2017)
7.	Ni, Zhaofei: 1 article (08/2017)
8.	Ren, Cuiping: 1 article (08/2017)
9.	Wang, Li: 1 article (08/2017)
10.	Zha, Xiaojun: 1 article (08/2017)

Related Diseases

1.	Proliferative Vitreoretinopathy 03/01/2003 - "Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy." 03/01/2003 - "The present study was designed to determine the effect of tyrphostin AG1295, a selective blocker of platelet-derived growth factor (PDGF) RTK, on proliferative vitreoretinopathy (PVR) development. "
2.	Ureteral Obstruction 01/01/2000 - "The current study was designed to investigate possible effects of the platelet-derived growth factor (PDGF) receptor kinase blocker AG1295 on the development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO), monitored by ED-A+ fibronectin expression, the number of macrophages, and the presence of myofibroblasts as visualized by immunohistochemistry with monoclonal antibodies (mAb) IST9, mAb ED1, and mAb 1A4, respectively; interstitial fibrosis was quantified by Sirius-Red staining and computer-aided image analysis. "
3.	Fibrosis (Cirrhosis) 01/01/2000 - "Treatment with AG1295 (12 mg/kg body weight, daily i.p.) significantly reduced interstitial fibrosis as verified by a smaller Sirius-Red stained area (15.7 +/- 1.9% in animals at 14 days and 17.0 +/- 0.7% at 21 days after UUO) and also by a reduced number of macrophages (12.8 +/- 1.4 in animals at 14 days and 15.5 +/- 3.8 at 21 days after UUO), and by the ED-A+ fibronectin deposition and the number of cells positive for alpha-smooth muscle actin. " 01/01/2000 - "The study indicates that the PDGF receptor kinase blocker AG1295 is able to decrease interstitial fibrosis in the rat UUO model significantly. " 01/01/2000 - "PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction." 01/01/2000 - "The current study was designed to investigate possible effects of the platelet-derived growth factor (PDGF) receptor kinase blocker AG1295 on the development of interstitial fibrosis in rats with unilateral ureteral obstruction (UUO), monitored by ED-A+ fibronectin expression, the number of macrophages, and the presence of myofibroblasts as visualized by immunohistochemistry with monoclonal antibodies (mAb) IST9, mAb ED1, and mAb 1A4, respectively; interstitial fibrosis was quantified by Sirius-Red staining and computer-aided image analysis. "
4.	Neoplasms (Cancer) 04/17/2003 - "AG1295 also delayed tumor formation and prolonged survival in an ESFT animal model. " 08/01/2008 - "Continuous administration of AG1295 (10 microg/h, s.c.), a PDGF receptor tyrosine kinase inhibitor, substantially suppressed DNA synthesis in the implanted tumor cells but not in the healthy bone marrow cells. " 08/15/2017 - "Therefore, downregulated FOXO3a/PDGFRα/AKT pathway exerts a protective effect against hyperactivated mTORC1-induced tumorigenesis caused by loss of TSC1/TSC2 complex, and the combination of rapamycin and AG1295 may be a new effective strategy for TSC-associated tumors treatment."
5.	Carcinogenesis 08/15/2017 - "Therefore, downregulated FOXO3a/PDGFRα/AKT pathway exerts a protective effect against hyperactivated mTORC1-induced tumorigenesis caused by loss of TSC1/TSC2 complex, and the combination of rapamycin and AG1295 may be a new effective strategy for TSC-associated tumors treatment."

Related Drugs and Biologics

1.	Platelet-Derived Growth Factor
2.	Tyrphostins
3.	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
4.	Phosphotransferases (Kinase)
5.	PDGF receptor tyrosine kinase
6.	Fibronectins (Fibronectin)
7.	Monoclonal Antibodies
8.	Becaplermin (PDGF-BB)
9.	Platelet-Derived Growth Factor alpha Receptor
10.	Sirolimus (Rapamycin)